Anticonvulsant, anti-depressant and potent teratogen. Inhibits histone deacetylase 1 (HDAC1) (IC50=0.4mM). Inhibitor of human cytochrome P450 2C9 isoform (Ki=600µM). Inducer of apoptosis in human leukemia cells. In nude mice experiments, inhibits significantly human uterine tumor growth without toxic side effects. Modulates the firing of neurons.
Product Details
Alternative Name: | 2-Propylpentanoic acid . Na, Sodium 2-propylpentanoate |
|
Formula: | C8H15O2 . Na |
|
MW: | 143.2 . 23.0 |
|
CAS: | 1069-66-5 |
|
MI: | 14: 9913 |
|
Purity: | ≥98% (GC) |
|
Appearance: | White to off-white powder. |
|
Solubility: | Soluble in water (50mg/ml) or 100% ethanol. |
|
Shipping: | Ambient Temperature |
|
Long Term Storage: | +4°C |
|
Handling: | Hygroscopic. |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
Histone deacetylase (HDAC) 1 controls the expression of beta defensin 1 in human lung epithelial cells: K. Kallsen, et al.; PLoS One
7, e50000 (2012),
Abstract;
Full Text
Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells: K. Huber, et al.; J. Biol. Chem.
286, 22211 (2011),
Abstract;
Full Text
Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1: S. Shetty, et al.; Mol. Cell. Biol.
25, 5404 (2005),
Abstract;
Full Text
Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells: N. Takai, et al.; Clin. Cancer Res.
10, 1141 (2004),
Abstract;
Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways: R. Kawagoe, et al.; Leuk. Res.
26, 495 (2002),
Abstract;
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen: C.J. Phiel, et al.; J. Biol. Chem.
276, 36734 (2001),
Abstract;
Full Text
In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9): X. Wen, et al.; Br. J. Clin. Pharmacol.
52, 547 (2001),
Abstract;
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells: M. Gottlicher, et al.; EMBO J.
20, 6969 (2001),
Abstract;
Mechanisms of action of valproate: a commentatory: C.U. Johannessen; Neurochem. Int.
37, 103 (2000), (Review),
Abstract;
Actions of sodium valproate on the central nervous system: G. Tunnicliff; J. Physiol. Pharmacol.
50, 347 (1999), (Review),
Abstract;
Maternal valproic acid and congenital neural tube defects: E. Robert & P. Guibaud; Lancet
2, 937 (1982),
Abstract;
The mechanism of action of sodium valproate: R.W. Kerwin & P.V. Taberner; Gen. Pharmacol.
12, 71 (1981), (Review),
Abstract;
Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy: R.M. Pinder, et al.; Drugs
13, 81 (1977), (Review),
Abstract;